H. Rogers

发表

Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test

T. Daly, M. Nakashima, X. Zhang, 2016, International journal of laboratory hematology.

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

F. Stingo, A. Bagg, P. Fox, 2014, Blood.

unclassifiable myelodysplastic/myeloproliferative neoplasms Atypical chronic myeloid leukemia is clinically distinct from

F. Stingo, A. Bagg, P. Fox, 2014 .

Laboratory Analysis of Coagulation

M. Nakashima, H. Rogers, K. Kottke-Marchant, 2014 .

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group

A. Bagg, D. Arber, Jacqueline S. Garcia, 2019, Modern Pathology.

SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts

A. Jankowska, C. O'keefe, J. Maciejewski, 2012, Leukemia.

COVID‐19 and the clinical hematology laboratory

H. Rogers, J. Frater, G. Zini, 2020, International journal of laboratory hematology.

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study

A. Bagg, A. Cherry, G. Raca, 2014, Haematologica.

De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study

D. Neuberg, V. Klepeis, A. Bagg, 2014, American journal of hematology.

Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).

E. Hsi, H. Rogers, H. J. Rogers, 2013, Surgical pathology clinics.

The World Health Organization (WHO) classification recognizes a group of myeloid neoplasms with overlapping features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms

A. Bagg, P. Fox, D. Arber, 2014 .

Myeloid/lymphoid neoplasms with FLT3 rearrangement

A. Bagg, David Wu, D. Arber, 2021, Modern Pathology.

Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia

T. Haferlach, J. Maciejewski, Y. Nagata, 2021, Leukemia.

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

J. Maciejewski, M. Sekeres, F. Traina, 2013, SAGE open medical case reports.

De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone

M. Sekeres, H. Rogers, R. Tiu, 2012, British journal of haematology.

Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants

M. Nakashima, H. Rogers, H. J. Rogers, 2014, Blood research.

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study

A. Bagg, D. Arber, S. Sadigh, 2018, Modern Pathology.

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome

A. Bagg, W. Tam, D. Arber, 2017, Haematologica.

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis

L. Zhang, M. Sekeres, M. Kalaycio, 2014, Leukemia.

Concurrent juvenile myelomonocytic leukemia and T‐lymphoblastic lymphoma with a shared missense mutation in NRAS

J. Maciejewski, H. Makishima, H. Rogers, 2014, Pediatric blood & cancer.

Thrombotic thrombocytopenic purpura: The role of ADAMTS13

H. Rogers, A. Lichtin, C. Allen, 2016, Cleveland Clinic Journal of Medicine.

Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms

T. LaFramboise, T. Haferlach, J. Maciejewski, 2020, Leukemia.

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

J. Maciejewski, H. Carraway, E. Hsi, 2021, Blood.

SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype

C. O'keefe, M. Sekeres, H. Makishima, 2013, Haematologica.

Running Title: SF3B1 and non-MDS and mast cell disease

C. O'keefe, M. Sekeres, H. Makishima, 2013 .

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts

Y. Saunthararajah, M. Sekeres, H. Rogers, 2015, Leukemia & lymphoma.

Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia

F. Solé, J. Maciejewski, Y. Nagata, 2020, Leukemia & lymphoma.

Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study

A. Bagg, D. Arber, L. Peterson, 2020, International journal of laboratory hematology.

Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia

M. Sekeres, E. Hsi, H. Rogers, 2015, Leukemia & lymphoma.

A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN

Y. Saunthararajah, M. Sekeres, F. Traina, 2012 .

UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia

M. Voso, J. Maciejewski, H. Rogers, 2022, HemaSphere.

The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult

H. Rogers, V. Visconte, Yan Xie, 2018, Blood research.

Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers

R. Tubbs, J. Bena, E. Hsi, 2014, Journal of Clinical Pathology.

T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group

A. Bagg, T. George, C. Bueso-Ramos, 2018, American journal of clinical pathology.

Pure Red Cell Aplasia in a Patient with Cri-Du-Chat

M. Sekeres, H. Rogers, V. Visconte, 2014 .

NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.

G. Pinkus, P. Cin, A. Bagg, 2022, Leukemia research.

A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria

A. Bagg, D. Arber, T. George, 2018, Modern Pathology.

Effect of 6% hydroxyethyl starch 130/0.4 on kidney and haemostatic function in cardiac surgical patients: a randomised controlled trial

I. İnce, H. Rogers, K. Kottke-Marchant, 2020, Anaesthesia.

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

A. Jankowska, C. O'keefe, J. Barnard, 2012, Blood.

Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction

A. Jankowska, C. O'keefe, J. Maciejewski, 2011 .

Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine

Y. Saunthararajah, M. Sekeres, M. Kalaycio, 2014, Leukemia & lymphoma.

Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study

A. Bagg, D. Arber, G. Borthakur, 2020, American journal of hematology.

Myeloid Neoplasms Associated with t(3;12)(q26.2;P13) Are Clinically Aggressive and Frequently Harbor FLT3 Mutations: A Report of 8 Cases and Review of Literature

C. Bueso-Ramos, Shaoying Li, C. Yin, 2014 .

Myeloid neoplasm with eosinophilia and ETV6-JAK2 fusion

H. Rogers, S. Mukherjee, J. Cook, 2020, Leukemia & lymphoma.

THE NORMAL BONE MARROW

H. Rogers, H. J. Rogers, 2019, Bone Marrow Pathology.